Purolite celebrates expansion of innovative bioprocessing facility in Wales
L-R: Hayley Crowe, Deputy Mayor Wendy Lewis, Chris Major, His Majesty's Lord-Lieutenant of Mid Glamorgan Peter Vaughan, Gergely Sved
Purolite, an Ecolab company, marked the opening of a new Customer Experience Centre featuring hands-on interactive and educational displays, showcasing the company’s expanded bioprocessing solutions.
Ecolab company Purolite held its ribbon-cutting ceremony on October 13 in celebration of their manufacturing expansion, which will see production capacity triple for the company’s bioprocessing resin production to meet global demands. In an interview with Chris Major, General Manager of the Bioprocessing division, Purolite’s expanded features will also bring attention to its commitment to the environmental impact of manufacturers.

L-R: Chris Major, Hayley Crowe, His Majesty's Lord-Lieutenant of Mid Glamorgan Peter Vaughan
The expansion includes a newly opened Customer Experience Centre featuring hands-on interactive and touch-screen educational displays showcasing Purolite’s bioprocessing solutions. As part of a multimillion-dollar global investment from Ecolab, increased office space, training areas, and conference room facilities will also be on offer.
Major stated: “It creates a space where our team can be really creative. When you’ve got some of the brightest minds in the industry, you want to have a nice place for them to work – you want to have a place where they feel inspired and where they can think about the next-generation products that are going to help impact the next generation of therapeutics, that’s what the innovation centre does. It creates an environment for our people to be free-thinking and innovative.”
Major emphasized Purolite’s continued commitment to bringing their customers sustainable processes and an ethical environment for their manufacturing needs. As a modular-built facility with 27 Portacabins, each cabin boasts the usage of second-use recycled steel. Groundwater heat pumps utilise thermal energy, which can be converted to use as renewable energy throughout the facility. Solar panels run the facility at close to net-zero energy. However Major noted that such facility features are only a small part of Purolite’s commitment to sustainability.

L-R: Hayley Crowe, Chris Major, Gergely Sved
“The big advantage that we have is the technology we have developed. For the last 50 years, there’s really been one method of manufacturing the type of technology that we do, and it has remained virtually unchanged since the 1950s. Over the last five to seven years, we’ve worked to revolutionise this type of a manufacturing method to something we’ve patented called ‘jetting method’. Jetting technology allows us to precisely control size to make uniform beads... By the way that we’ve designed and implemented this manufacturing technology, we’ve been able to substantially reduce the amount of water (compared to the traditional manufacturing method).” In addition to reducing water usage and wastage, Major also stated that carbon dioxide emissions were significantly reduced with the patented jetting method, as well as almost eliminating harmful solvents. With sustainable manufacturing methods, Major highlights that Purolite not only reduces their own environmental impact but also that of their customers who choose to partner with them.
The expanded facility in Wales runs in parallel to construction at Purolite’s facility in the United States, giving Purolite a dual-continent capability to make innovative therapeutics around the world accessible. Major emphasized that a pillar of Purolite’s ethos is not only to develop and manufacture exciting new technologies in support of biopharmaceuticals, but to also make healthcare an accessible right across the globe.
Major concluded with a highlight of some of Purolite’s business achievements, including a series of global awards and recognitions. Purolite UK was awarded the Queen's Award for Enterprise in 2022, given by His Majesty’s Lord Lieutenant of Mid Glamorgan. With a wider global footprint, Purolite’s headcount has almost doubled, something Major anticipates will only increase in the coming years. The Wales Business Award for Most Innovative Company was also presented to Purolite, further demonstrating Purolite’s commitment and production of cutting-edge technology.
Read more about Purolite’s expansion here.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...